Sensitive quantitative and rapid immunochromatographic

diagnosis of clinical samples by scanning electron microscopy -

preparing for future outbreaks

Running title: Immunochromatographic diagnosis of disease by SEM

Hideya Kawasaki*[a], Hiromi Suzuki[a], Masato Maekawa[b], Takahiko Hariyama*[a]

[a] Institute for NanoSuit Research, Preeminent Medical Photonics Education &

Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan

[b] Department of Laboratory Medicine, Hamamatsu University School of Medicine,

Hamamatsu, Japan

* Corresponding authors: Hideya Kawasaki, Takahiko Hariyama

Email: gloria@hama-med.ac.jp, hariyama@hama-med.ac.jp

ORCID account: 0000-0001-8923-7722, 0000-0001-9623-1011

Author Contributions: H.K. designed research; H.K., H.S., performed research;

H.K. M.M., analyzed data; and H.K., T.H. wrote the paper.

Abbreviations: EM, Electron microscopy; LAMP, loop-mediated isothermal

amplification; SEM, scanning electron microscope; GNP, gold nanoparticles;

INSM, immunochromatography-NanoSuit® method; PCR, polymerase chain

reaction; rRT-PCR, real-time reverse transcription-polymerase chain reaction, IgG,

immunoglobulin G; IgM, immunoglobulin M

Abstract

Background: As pathogens such as influenza virus and severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2) can easily cause pandemics, rapid

diagnostic tests are crucial for implementing efficient quarantine measures,

providing effective treatments to patients, and preventing or containing a pandemic

infection. Here, we developed the immunochromatography-NanoSuit® method, an

improved immunochromatography method combined with a conventional scanning

electron microscope (SEM), which enables observation of immunocomplexes

labeled with a colloidal metal.

Methods and Findings: The detection ability of our method is comparable to that

of real-time reverse transcription-polymerase chain reaction and the detection time

is approximately 15 min. Our new immunochromatography-NanoSuit® method

suppresses cellulose deformity and makes it possible to easily focus and acquire

high-resolution images of gold/platinum labeled immunocomplexes of viruses such

as influenza A, without the need for conductive treatment as with conventional

SEM. Electron microscopy (EM)-based diagnosis of influenza A exhibited 94%

clinical sensitivity (29/31) (95% confidence interval [95%CI]: 78.58–99.21%) and

100% clinical specificity (95%CI: 97.80–100%). EM-based diagnosis was

significantly more sensitive (71.2%) than macroscopic diagnosis (14.3%),

especially in the lower influenza A-RNA copy number group. The detection ability

of our method is comparable to that of real-time reverse transcription-polymerase

chain reaction.

Conclusions: This simple and highly sensitive quantitative analysis method

involving immunochromatography can be utilized to diagnose various infections in

humans and livestock, including highly infectious diseases such as COVID-19.

Introduction

Infections are major threats to humanity. The novel influenza A (H1N1) pdm09 was

declared a pandemic in 2009 [1], and the current 2020 severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a devastating impact

on human health and the world economy. The following factors are crucial for

reducing the effects of these infections: 1: delayed invasion of infection into the

country because of border measures and quarantine, 2: early containment

strategies, 3: early diagnosis enabling appropriate treatment, and 4:

broad antibody (IgM, IgG) and/or antigen testing against the virus to assess the

spread of the virus. Therefore, rapid diagnostic tests are crucial for disease

prevention, treatment, and pandemic containment [2]. Although real-time reverse

transcription-polymerase chain reaction (rRT-PCR) is a sensitive method, it is time-

consuming, costly, and requires special equipment with professional expertise and

high-quality samples. For point-of-care testing, immunochromatography is easier

to perform and useful for prompt disease detection, but its sensitivity and specificity

are lower than those of rRT-PCR. However, improved specificity has been

achieved by using lateral flow biosensors (LFBs) with micro- and nano-materials

[3]. Signal readouts based on color, electrochemical signals, magnetic properties,

luminescent, and surface-enhanced Raman spectroscopy have been integrated

with LFBs for quantification analyses [3,4]. Nevertheless, these nanoparticle

sensing methods are indirect. Direct observation of metal nanoparticles by electron

microscopy (EM) for clinical use has not been reported because of the complexity

of sample preparation and conventional EM operation. We recently reported a

method for evaluating multicellular organisms in high vacuum of an EM by

encasing them in a thin, vacuum-proof suit, the 'NanoSuit®' [5], which can impart

conductivity to a wet sample to avoid electron charges. Here, we combined the

NanoSuit® method with immunochromatography. The new

immunochromatography-NanoSuit® method (INSM) suppresses the deformity of

the immunochromatography substrate such as cellulose, which causes blurring of

particle images, and enables easy focus and acquisition of high-resolution images

without the need for additional conductive treatment [6] as with a conventional

scanning EM (SEM). In the medical field, using rRT-PCR and INSM as two

sensitive rapid diagnostic tests will help maintain patient health. INSM also is a

highly sensitive diagnostic tool for several pathogenic infections or other diagnoses.

Methods

Ethical statement

The study was approved by the Hamamatsu University School of Medicine ethical

committee (No. 19-134), and all methods were performed following relevant

guidelines and regulations.

Immunochromatography kit

The ImunoAce® Flu kit (NP antigen detection), a human influenza commercial

diagnosis kit, was purchased from TAUNS Laboratories, Inc. (Shizuoka, Japan).

Au/Pt nanoparticles were utilized to visualize the positive lines. A total of 197

clinical samples from patients suspected to be suffering from influenza were

provided by a general hospital at the Hamamatsu University School of Medicine

for examination using the Flu kit. After macroscopic diagnosis using the Flu kit, the

samples were stored in a biosafety box at room temperature (20-25 °C / 68 - 77 °F).

The IgM detection immunochromatography kit against SARS-CoV-2 was obtained

from Kurabo Industries, Ltd. (Osaka, Japan).

One step rRT-PCR for influenza A

rRT-PCR for influenza A was performed as described previously using Flu A

universal primers [7]. A Ct within 38.0 was considered as positive according to the

CDC protocol [8]. The primer/probe set targeted the human RNase P gene and

served as an internal control for human nucleic acid as described previously [9].

SEM image acquisition

The immunochromatography kit was covered with modified NanoSuit® solution

based on previously published components [5] (Nisshin EM Co., Ltd., Tokyo,

Japan), placed first onto the wide stage of the specimen holder, and then placed

in an Lv-SEM (TM4000Plus, Hitachi High-Technologies, Tokyo, Japan). Images

were acquired using backscattered electron detectors with 10 or 15 kV at 30 Pa.

Particle counting

In fields containing fewer than 50 particles/field, the particles were counted

manually. Otherwise, ImageJ/Fiji software was used for counting. ImageJ/Fiji uses

comprehensive particle analysis algorithms that effectively count various particles.

Images were then processed and counting was performed according to the

protocol [10].

Diagnosis and statistics

The EM diagnosis and criteria for a positive test were defined as follows: particle

numbers from 6 fields from the background area and test-line were statistically

analyzed using the t-test. If there were more than 5 particles in one visual field and

a significant difference ($P < 0.01$) was indicated by the t-test, the result was

considered as positive. Statistical analysis using the t-test was performed in Excel

software. Statistical analysis of the assay sensitivity and specificity with a 95%

confidence interval (95% CI) was performed using the MedCalc statistical website.

The approximate line, correlation coefficient, and null hypothesis were calculated

with Excel software.

Results

To investigate the sensitivity and specificity of immunochromatography using the

NanoSuit® method, an influenza diagnostic kit (TAUNS Laboratories, Inc.) was

prepared (**Fig. 1*A***). Two specific antibodies were used: one (anti-mouse IgG or

anti-influenza A NP) was immobilized on chromatographic paper, whereas the

other was labeled with colloidal gold/platinum (100−200 nm in diameter) and

infiltrated into the sample pad. The kit was completed by attaching the sample pad

at the end of the membrane. When the clinical sample in lysis buffer (150 L) was

placed on the sample pad, the virus antigen in the sample formed an

immunocomplex with the colloidal gold/platinum- labeled antibody, which

subsequently formed an immune complex with the antibody immobilized on the

membrane, resulting in the generation of colored lines and indicating the presence

of the antigen of interest in the sample (**Fig. 1*B* top, middle**). After the reaction,

NanoSuit® solution (100 μL) was added upstream of the test-line (**Fig. 1*B* middle**),

forming a thin NanoSuit® liquid layer (pale blue) (**Fig. 1*B* bottom**). The kit was

positioned on the sample stage in the sample chamber of the SEM as close and

parallel as possible to the camera (**Fig. 1*C***). The observation position of the test-

line and background area were determined at fixed distances from the control-line

border. The number of Au/Pt particles at the test-line and background area were

counted in 6 fields of view at ×1200 (**Fig. 1D**). Without NanoSuit® treatment,

swelling of the cellulose and residual liquid present due to electron beam energy

were observed (**Fig. 2A**). In contrast, following NanoSuit® treatment, the cellulose

membrane showed little or no swelling (**Fig. 2B**).

The SEM images of the test lines and background were compared. **Figure 3A,**

D show the "macroscopic diagnosis-positive" test-line. **Figure 3B, E** are images of

the "macroscopic diagnosis-negative" and "EM diagnosis-positive" test-line.

Figure 3C, **F** are the images of the background. Au/Pt particles (arrows) of the

test-line were clearly visualized (**Fig. 3A, B, D, E**) compared to background areas

of the cellulose membrane (**Fig. 3C, F**). Au/Pt particle counting was performed by

using ImageJ/Fiji software for macroscopic diagnosis-positive samples. Manual

counting was performed for the images of "background" and "macroscopic

diagnosis negative and SEM diagnosis-positive" samples as well as "EM-negative"

samples. Another immunochromatography diagnosis kit for detecting IgM

antibodies against SARS-CoV-2 from Kurabo Industries, Ltd. was tested using the

NanoSuit® method (**S1A Fig**). The cellulose membrane image without the

immunocomplex was clearly visualized after NanoSuit® treatment (**S1B Fig**).

Approximately 25-nm countable gold nanoparticles (GNPs) of the control-line were

detected (**S1*C* Fig).**

Diagnoses based on macroscopic, EM, and rRT-PCR results were compared

using the 197 influenza-suspected clinical samples. rRT-PCR for influenza A was

performed with the same clinical pharyngeal swab samples as used in

immunochromatography. To examine the relationship between the influenza copy

number and rRT-PCR threshold, serial dilutions were prepared (**S2*A* Fig**). A

calibration curve (**S2*B* Fig**) was drawn to determine the relationship between the

copy number and cycle threshold (Ct) (**S2*C* Fig**). In our assay system, Ct ≤ 38.0

was calculated to be ≥ 151.4 copies/reaction.

The quantitative relationship between particle counts/fields (log10) and Ct are

shown as a scatter diagram. The correlation coefficient of Ct and particle

counts/field was -0.803, which was significant (p = 3.79E-08) and the null

hypothesis was rejected (**Fig. 4**) (**Supplemental data**).

The EM diagnosis for influenza A showed 94% clinical sensitivity (29/31) (95%

confidence interval [95%CI]: 78.58–99.21%) and 100% clinical specificity (95%CI:

97.80–100%) (**Table 1**) (**Supplemental data**), as well as a strong correlation

(kappa; 0.99) compared with the results obtained by rRT-PCR (14.0 ≤ Ct ≤ 38.0)

(**Table 2**) (**Supplemental data**). In contrast, standard macroscopic diagnosis

showed 77% clinical sensitivity (24/31) (95%CI: 58.90–90.41%) and 100% clinical

specificity (95%CI: 97.80–100%) (**Table 1**) (**Supplemental data**), along with a

strong correlation (kappa; 0.96) compared with the results obtained by rRT-PCR

(14.0 ≤ Ct ≤ 38.0) (**Table 2**)(**Supplemental data**).

Discussion

Rapid diagnostic tests show variable assay performance with sensitivities of 10–

70% and up to 90% specificity compared to standard rRT-PCR-based assays [11].

Their sensitivity has been improved by employing europium nanoparticles, which

show 82.59% sensitivity and 100% specificity for clinically evaluated influenza A

(H1N1) [12]. The use of silver amplification immunochromatography in influenza

virus detection kits showed 91.2% sensitivity and 95.8% specificity [13]. Moreover,

the rapid fluorescent immunochromatographic test employing CdSe/CdS/ZnS

quantum dots showed 93.75% clinical sensitivity and 100% clinical specificity [14].

However, the potential toxic effects of cadmium-based quantum dots are

controversial [15]. INSM is safe and showed the highest sensitivities (94% clinical

sensitivity, 100% clinical specificity) in this study. Generally, overall sensitivity

depends on the distribution of each sample's pathogen-copy number in the

investigated group. Our study revealed that EM diagnosis was significantly more

sensitive (71.2%) than macroscopic diagnosis (14.3%) in the lower copy number

group (30.0 ≤ Ct ≤ 38). The detection ability of our method is comparable to that of

rRT-PCR (**Fig. 4**). Theoretically and practically, our method shows the highest

detection performance as an immunochromatographic diagnostic method. More

sensitive immunochromatographic products may be developed in future through

further improvements such as by optimizing the antigen concentration.

PCR has recently been used as a main diagnostic tool for SARS-CoV-2. The

introduction of immunochromatography analysis using the SARS-CoV-2 antigen

has greatly changed testing practices. All immunochromatographic-negative

SARS-CoV-2-suspected samples are recommended for analysis by PCR. Highly

sensitive immunochromatographic tests for infectious diseases can greatly reduce

the number of PCR samples to be analyzed. Furthermore, Cohen and Kessel

reported high false-positive rates of RT-PCR testing for SARS-CoV-2 using clinical

samples. Overall, 336 of 10,538 negative samples (3.2%) were reported as

positive. In contrast, <0.6–7.0% false-positive rates in external quality

assessments of RNA virus assays were reported for influenza A. The amplification

of nucleic acids makes PCR-based assays highly sensitive but highly vulnerable

to minute levels of sample contamination which can produce false-positive results

indistinguishable from true-positive results [16]. The same pitfall may be found in

Loop-Mediated Isothermal Amplification (LAMP) method. We propose that

macroscopic immunochromatographic-negative and PCR- or LAMP-positive

cases should be compared with highly sensitive immunochromatographic data

such as that obtained by INSM as well as clinical data to reduce false-positive

cases.

Although ImageJ/Fiji is useful software, it should be further developed to

increase its reliability. The development of an automated GNP counting system to

replace manual counting using deep learning is being evaluated by our team.

Furthermore, clinical application of using an automated inexpensive SEM for

immunochromatography in combination with INSM for SEM shows potential.

Among the commonly used micro/nano-particles in immunochromatography,

colloidal GNP is the most widely used [3]. GNP is safe and can be easily

conjugated with biomolecules that retain their biochemical activity upon binding.

Therefore, developing new GNP-based LFBs may be easier and faster than

developing micro/nano-materials and can be adapted quickly for new emerging

infections such as SARS-CoV-2 [17]. Investigation of INSM using smaller GNPs is

currently underway. INSM is applicable to all LFBs, particularly in emergency tests

to evaluate troponin, brain natriuretic peptide, and procalcitonin as measured by

immunochromatography.

Diagnosis using the INSM shows high sensitivity, as it allows for direct particle

observation. Our results indicate that INSM can be used for automated quantitative

measurement in any immunochromatographic tests including recently developed

SARS-CoV-2 antigen or IgM/IgG antibodies tests against SARS-CoV-2. This

method can be used to promptly diagnose new emerging infections including those

in livestock and promote innovations in assays using LFBs.

Acknowledgments

The authors thank Noriko Aoki (TAUNS Laboratories, Inc.) for providing rRT-PCR

data on influenza A and Takafumi Miwa and Takumi Tandou (Hitachi, Ltd.

Research & Development Group Nano-process Research Department) for

advising on SEM. We also thank the clinical laboratory center of Hamamatsu

University School of Medicine, University Hospital for providing influenza

immunochromatography test strips after routine examinations. This work was

supported by JST START (grant number 714 [to H.K.]), JSPS KAKENHI (grant

numbers JP17K08784 [to H.K.] and JP18H01869 [to T.H.]), and AMED (grant

number A508 [to H.K.]).

Competing interests

261   The authors declare no competing interests.

References

[1] Swerdlow DL, Finelli L. Preparation for possible sustained transmission of 2019 novel coronavirus: lessons from previous epidemics. JAMA. 2020;323: 1129-1130.

[2] Ravina R, Dalal A, Mohan H, Prasad M, Pundir CS. Detection methods for influenza A H1N1 virus with special reference to biosensors: a review. Biosci Rep. 2020;40.

[3] Huang Y, Xu T, Wang W, Wen Y, Li K, Qian L, et al. Lateral flow biosensors based on the use of micro- and nanomaterials: a review on recent developments. Mikrochim Acta. 2019;187: 70.

[4] Urusov AE, Zherdev AV, Dzantiev BB. Towards lateral flow quantitative assays: detection approaches. Biosensors (Basel). 2019;9.

[5] Takaku Y, Suzuki H, Ohta I, Ishii D, Muranaka Y, Shimomura M, et al. A thin polymer membrane, nano-suit, enhancing survival across the continuum between air and high vacuum. Proc Natl Acad Sci USA. 2013;110: 7631-7635.

[6] Kawasaki H, Itoh T, Takaku Y, Suzuki H, Kosugi I, Meguro S, et al. The NanoSuit method: a novel histological approach for examining paraffin sections in a nondestructive manner by correlative light and electron microscopy. Lab Invest 2020;100: 161-173.

[7] de-Paris F, Beck C, Machado ABMP, Paiva RM, da Silva Menezes D, de Souza Nunes L, et al. Optimization of one-step duplex real-time RT-PCR for detection of

282   influenza and respiratory syncytial virus in nasopharyngeal aspirates. J Virol

283   Methods. 2012;186: 189-192.

284   [8]   CDC. Division CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel

285   (CDC Flu rRT-PCR Dx Panel). 2014. Available from:

286   https://journals.plos.org/plosone/article/file?type=supplementary&id=info:doi/10.1

287   371/journal.pone.0201248.s007.

288   [9]   WHO Collaborating Centre for Influenza, GA. CDC protocol of realtime RTPCR for

289   influenza A (H1N1) 2009. Available from:

290   https://www.who.int/csr/resources/publications/swineflu/realtimeptpcr/en/.

291   [10]   O'Brien J, Hayder H, Peng C. Automated quantification and analysis of cell

292   counting procedures using ImageJ plugins. J Vis Exp. 2016;17: 54719.

293   [11]   Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current approaches for

294   diagnosis of influenza virus infections in humans. Viruses. 2016;8: 96.

295   [12]   Yu ST, Bui CT, Kim DTH, Ngyuen AVT, Trinh TTT, Yeo SJ. Clinical evaluation of

296   rapid fluorescent diagnostic immunochromatographic test for influenza A virus

297   (H1N1). Sci Rep. 2018;8: 13468.

298   [13]   Mitamura K, Zhimizu H, Yamazaki M, Ichikawa M, Nagai K, Katada J, et al. Clinical

299   evaluation of highly sensitive silver amplification immunochromatography systems

300   for rapid diagnosis of influenza. J Virol Methods. 2013;194: 123-128.

301   [14]   Nguyen AVT, Dao TD, Trinh TTT, Choi DY, Yu ST, Park H, et al. Sensitive

302   detection of influenza a virus based on a CdSe/CdS/ZnS quantum dot-linked rapid

303   fluorescent immunochromatographic test. Biosens Bioelectron. 2020;155: 112090.

304   [15]   Oh E, Liu R, Nel A, Gemill KB, Bilal M, Cohen Y, et al. Meta-analysis of cellular

305   toxicity for cadmium-containing quantum dots. Nat Nanotechnol. 2016;11: 479-486.

306   [16]   Cohen AN, Kessel B. False positives in reverse transcription PCR testing for

307   SARS-CoV-2. medRxiv. 2020.

308   [17]   Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat

309   Biotechnol. 2020;38: 515-518.

Figure 1. Sensitivity and specificity of immunochromatography using the

NanoSuit® method. (**A**) Kit representation showing test and control lines. (**B**)

Schematic diagram of the gold/platinum (Au/Pt)-Ab conjugate-linked rapid

immunochromatographic kit. The immune-complex reacted with the anti-influenza

A nucleoprotein (NP) at the test line and anti-mouse IgG at the control-line (top,

middle). A NanoSuit® thin layer was formed after NanoSuit® treatment (bottom).

(**C**) Kit placement in the SEM chamber. (**D**) Determination of the observation

positions. Six fields were randomly selected in the test line and background areas.

Figure 2. (**A, B**) Images of cellulose and Au/Pt-labeled immunocomplex with

immobilized antibody without (**A**) and with NanoSuit treatment (**B**). Scale bars in

(**A**) and (**B**) = 15 µm. Inset is magnified image. Scale bars 600 nm.

Figure 3. Comparison of SEM images of test lines and of background. (**A, D**) images of "macroscopic diagnosis-positive" test-line. (**B, E**) Images of "macroscopic diagnosis-negative" and "EM diagnosis-positive" test-line. (**C, F**) Images of "background". White arrows indicate representative Au/Pt particles. Scale bars in (**A, B, C**) = 30 µm and (**D, E, F**) = 3 µm.

Figure 4. Scatter plot of Ct and particle counts/field. Blue dot represents triple-

positive ("macroscopic diagnosis-positive" and "EM diagnosis-positive" and "PCR

diagnosis-positive"). Red dot represents double-positive ("EM diagnosis-positive"

and "PCR diagnosis-positive"). Green dot represents single-positive ("PCR

diagnosis-positive"). Blue dot line is approximate curve. Vertical axis: particle

counts (log10)/field. Horizontal axis: Ct of influenza A.

Tables

Influenza A rRT-PCR	Ct	Macroscopic diagnosis		Electron microscopic diagnosis	
		Sensitivity	Specificity	Sensitivity	Specificity
Positive (n=31)	14.0≤Ct<22.0	100% (3/3)		100% (3/3)	
	22.0≤Ct<30.0	95.2% (20/21)		100% (21/21)	
	30.0≤Ct≤38.0	14.3% (1/7)		71.4% (5/7)	
	14.0≤Ct≤38.0	77.4% (24/31)		93.5% (29/31)	
Negative (n=166)	Ct>38.0		100% (166/166)		100% (166/166)

345   **Table 1.** Clinical diagnostic performance of EM assay. Thirty-one influenza A-rRT-

346   PCR-positive samples were used to determine the sensitivity of the assays, and

347   166 influenza rRT-PCR-negative samples were used to determine the specificity

348   of the assays.

		Macroscopic diagnosis			Electron microscopic diagnosis		
		positive	negative	Row Marginal	positive	negative	Row Marginal
Influenza A rRT-PCR	Positive	24	7	31	29	2	31
	Negative	0	166	166	0	166	166
Column Marginal		24	172	197	29	168	197
% Agreement(kappa)		0.96: 24+166/197			0.99: 29+166/197		

Table 2. Comparison of EM diagnosis with rRT-PCR and macroscopic diagnosis

by immunochromatography.

Supplemental Figures and Data

Supplemental Figure 1. (*A*) Immunochromatography diagnosis kit for IgM

antibody against SARS-CoV-2. (*B*) Background image. (*C*) Multiple gold

nanoparticles (GNPs) (approximately 25-nm diameter) of the control-line on

cellulose. White arrows indicate representative GNPs. Scale bars in (**B**) and (**C**) =

600 nm.

Supplemental Figure 2. Comparison of macroscopic, electron microscopic (EM) and rRT-PCR influenza A diagnoses. (***A***) rRT-PCR amplification curve for influenza A. (***B***) Standard curve for rRT-PCR of influenza A. (***C***) Relationship between cycle threshold (Ct) and sample copy numbers/reaction.

Case	Macroscopic Diagnosis	Electron Microscopic Diagnosis	BG:1 particles/field	BG:2 particles/field	BG:3 particles/field	BG:4 particles/field	BG:5 particles/field	BG:6 particles/field	Average BG	TL:1 particles/field	TL:2 particles/field	TL:3 particles/field	TL:4 particles/field	TL:5 particles/field	TL:6 particles/field	Average TL	t-test	Diagnosis	rRT-PCR	CT1	CT2	Average CT	Diagnosis
No.1	positive		2	2	3	0	1	3	1.83333333	1057	886	1472	1005	1026	1241	1114.5	2.34304E-05	positive		27.13	27.19	27.16	positive
No.2	positive		9	12	6	7	12	16	10.3333333	1459	2104	1482	759	2424	1292	1586.666667	0.00063971	positive		23.46	23.65	23.51	positive
No.3	positive		26	17	17	12	11	27	18.3333333	343	362	291	332	259	365	325.3333333	3.06815E-06	positive		28.49	28.46	28.48	positive
No.4	positive		48	42	24	39	19	20	32	1839	1401	1610	1897	2140	1293	1696.666667	2.67998E-05	positive		26.21	26.21	26.21	positive
No.5	positive		3	2	0	3	3	4	2.5	332	320	301	291	203	339	297.6666667	1.39772E-05	positive		27.16	27.18	27.17	positive
No.6	positive		11	7	34	17	27	16	18.6666667	2153	3166	1169	2059	1880	1307	1955.666667	0.000616081	positive		26.12	26.2	26.16	positive
No.7	positive		15	17	2	15	8	14	11.8333333	987	1334	887	1458	1294	1298	1209.666667	2.04264E-05	positive		16.3	16.37	16.33	positive
No.8	positive		14	8	5	5	17	18	11.1666667	1162	1570	2462	2013	2375	2404	1997.666667	0.000128189	positive		22.78	22.85	22.82	positive
No.9	positive		13	31	16	20	8	23	18.5	913	559	811	688	669	1083	787.1666667	9.16168E-05	positive		22.58	22.68	22.63	positive
No.10	positive		21	28	16	16	18	8	17.8333333	972	1037	556	1160	566	1468	959.8333333	0.000644387	positive		27.64	27.59	27.62	positive
No.11	positive		5	5	5	7	4	3	4.83333333	1077	1741	2682	1548	1726	2736	1918.333333	0.000425094	positive		32.7	32.83	32.57	positive
No.12	positive		0	1	0	2	2	6	1.83333333	1682	1984	2295	1973	2081	1417	1905.333333	1.21327E-05	positive		25.1	25.1	25.1	positive
No.13	positive		32	35	15	8	19	12	20.1666667	2981	2579	3371	3044	3232	3090	3049.5	6.83137E-07	positive		18.21	18.15	18.18	positive
No.14	positive		34	36	12	8	12	13	19.1666667	2861	2748	2548	2774	1634	1770	2389.166667	5.91063E-05	positive		22.33	22.49	22.41	positive
No.15	positive		55	22	25	46	60	34	40.3333333	1152	606	490	503	442	399	598.6666667	0.002101821	positive		27.54	27.48	27.51	positive
No.16	positive		42	12	30	27	42	34	31.1666667	1927	988	1100	1162	1339	2577	1515.5	0.000959966	positive		27.85	27.88	27.87	positive
No.17	positive		1	0	3	1	1	2	1.33333333	196	243	171	142	151	244	191.1666667	7.12664E-05	positive		28.99	28.85	28.92	positive
No.18	positive		14	7	4	1	4	4	5.66666667	2207	1756	2748	2085	1766	2087	2108.166667	1.58095E-05	positive		23.33	23.55	23.29	positive
No.19	positive		0	0	2	2	1	3	1.33333333	874	648	993	1153	1280	1055	1000.5	5.17775E-05	positive		20.23	20.29	20.26	positive
No.20	positive		9	1	1	5	11	4	5.5	1776	2260	1765	1605	1866	2106	1896.333333	3.70512E-06	positive		24.1	24.04	24.07	positive
No.21	positive		36	40	37	11	7	4	22.5	2280	2380	2036	2093	2056	1840	2114.166667	4.91638E-07	positive		24.05	24.13	24.09	positive
No.22	positive		2	1	0	1	0	2	1	1163	881	1034	1005	1327	1027	1072.833333	6.28819E-06	positive		25.52	25.51	25.52	positive
No.23	positive		1	0	0	0	0	0	0.16666667	160	187	103	107	92	109	126.3333333	0.000222593	positive		27.85	27.91	27.88	positive
No.24	positive		0	0	0	0	0	1	0.16666667	1156	1487	1377	1403	1448	1308	1363.166667	5.30624E-07	positive		27.24	24.33	27.29	positive
No.25	negative		2	1	1	1	1	3	1.5	6	1	7	8	8	9	6.5	0.003016442	positive		32.76	32.66	32.71	positive
No.26	negative		2	1	0	3	2	1	1.5	18	16	25	20	12	9	16.66666667	0.000789827	positive		29.55	29.5	29.53	positive
No.27	negative		2	0	0	4	0	1	1.16666667	8	5	4	5	5	7	5.666666667	0.001001171	positive		32.73	32.76	32.75	positive
No.28	negative		0	2	2	0	1	1	1	6	5	7	7	11	6	7	0.001112374	positive		33.92	33.56	33.94	positive
No.29	negative		2	4	3	2	1	3	2.5	8	5	3	4	6	5	5.166666667	0.000796697	positive		35.55	35.11	35.65	positive
No.30	negative		15	10	5	8	4	10	8.66666667	12	15	11	8	11	8	10.83333333	0.138669902	negative		35.72	35.77	35.75	positive
No.31	negative		2	0	5	0	0	2	1.5	1	5	2	6	4	7	4.166666667	0.069889516	negative		37.83	37.63	37.73	positive

Supplemental Data. Comparison of among macroscopic diagnosis, EM diagnosis and rRT-PCR diagnosis. BG: Background, TL: Test Line

A

control line   test line

B

Flow

Au Pt

Lysis Buffer
Influenza virus

Anti-mouse IgG   Anti-Influenza A NP

15 min

NanoSuit Solution

Control line   Test line

NanoSuit thin layer

Control line   Test line

C

D

7.8 mm

6.8 mm

control line   test line

Influenza A rRT-PCR	Ct	Macroscopic diagnosis		Electron microscopic diagnosis	
		Sensitivity	Specificity	Sensitivity	Specificity
Positive (n=31)	14.0≤Ct<22.0	100% (3/3)		100% (3/3)	
	22.0≤Ct<30.0	95.2% (20/21)		100% (21/21)	
	30.0≤Ct≤38.0	14.3% (1/7)		71.4% (5/7)	
	14.0≤Ct≤38.0	77.4% (24/31)		93.5% (29/31)	
Negative (n=166)	Ct>38.0		100% (166/166)		100% (166/166)

		Macroscopic diagnosis			Electron microscopic diagnosis		
		positive	negative	Row Marginal	positive	negative	Row Marginal
Influenza A rRT-PCR	Positive	24	7	31	29	2	31
	Negative	0	166	166	0	r166	166
Column Marginal		24	172	197	29	168	197
% Agreement(kappa)		0.96: 24+166/197			0.99: 29+166/197		